CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking.
The chemokine receptors (CCRs) CCR4 and CCR10, and the cutaneous lymphocyte antigen (CLA), have each been proposed as critical mediators of skin-specific TH lymphocyte homing in mice and humans. CLA initiates skin homing by mediating E-selectin-dependent tethering and rolling within cutaneous venules, but the specific roles of CCR4 and CCR10 are unclear. We have generated an antihuman CCR10 monoclonal antibody (mAb; 1B5) to illuminate the individual contributions of these molecules. This mAb allows us to compare CCR10, CCR4, and CLA expression within human TH populations. The mAb 1B5 recognizes functional CCR10 expression, as chemotactic responsiveness to cutaneous T-cell-attracting chemokine (CTACK)/CCL27 (a CCR10 ligand) parallels the staining of TH subsets. We find CCR10 expressed by only a minority (approximately 30%) of blood-borne, skin-homing (CLA+/CCR4+) TH cells. However, essentially all members of the relatively small "effector" (CLA+/CCR4+/CD27-/CCR7-) skin-homing TH population express CCR10. Most skin-infiltrating lymphocytes in allergic delayed-type hypersensitivity (DTH) and bacterial chancroid skin lesions express both CCR4 and CLA, but only about 10% express CCR10. This suggests for the 2 models of TH skin homing studied here that CCR10+ TH cells have no advantage over other CLA+/CCR4+ TH cells in homing to cutaneous sites. We conclude that the skin-homing TH compartment is itself divided into distinct subpopulations, the smaller of which expresses both CCR4 and CCR10, and the larger of which expresses only CCR4. Thus, CCR10 is unlikely to be necessary for cutaneous homing of TH cells in the models studied here. CCR10 may instead play a role in the movement of specialized "effector" cutaneous TH cells to and/or within epidermal microenvironments.
Soler
Dulce
D
Millennium Pharmaceuticals, Inflammation Department, Cambridge, MA 02115, USA.
Humphreys
Tricia L
TL
Spinola
Stanley M
SM
Campbell
James J
JJ
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000945:Antigens, Differentiation, T-Lymphocyte; D000951:Antigens, Neoplasm; D002602:Chancroid / Q000276:immunology / Q000473:pathology; D054425:Chemokine CCL27; D019742:Chemokines, CC / Q000494:pharmacology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007156:Immunologic Memory; D016130:Immunophenotyping; D036904:Leukocyte Rolling / Q000187:drug effects / Q000502:physiology; D016393:Lymphoma, B-Cell / Q000473:pathology; D008562:Membrane Glycoproteins / Q000032:analysis; D051379:Mice; D008810:Mice, Inbred C57BL; D054447:Receptors, CCR10; D054398:Receptors, CCR4; D019707:Receptors, Chemokine / Q000235:genetics / Q000276:immunology / Q000502:physiology*; D012867:Skin / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000166:cytology* / Q000187:drug effects; D014157:Transcription Factors / Q000276:immunology / Q000502:physiology*; D014162:Transfection; D014407:Tumor Cells, Cultured
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D000951:Antigens, Neoplasm; C492276:CCL27 protein, human; C515706:CCR10 protein, human; C515354:CCR4 protein, human; C063419:CTAGE1 protein, human; C119538:Ccl27a protein, mouse; C515707:Ccr10 protein, mouse; C515355:Ccr4 protein, mouse; D054425:Chemokine CCL27; D019742:Chemokines, CC; D008562:Membrane Glycoproteins; D054447:Receptors, CCR10; D054398:Receptors, CCR4; D019707:Receptors, Chemokine; D014157:Transcription Factors